SOLAR-1

Background

Phase III, double-blind, placebo-controlled RCT. N=572 HR+ HER2- advanced breast cancer progressing on/after prior endocrine therapy. PIK3CA status assessed prospectively (ctDNA or tumor tissue). Alpelisib is a PI3Kα-selective inhibitor; PIK3CA mutation was the biomarker selection criterion.

Interventions and follow up

Arm A: Alpelisib 300mg daily + fulvestrant 500mg IM q28d
Arm B: Placebo + fulvestrant 500mg IM q28d
Primary endpoint: PFS in PIK3CA-mutated cohort
mFollow up: 20 months

Results

PFS (PIK3CA-mutated, n=341): 11.0 vs 5.7mo, HR 0.65, 95% CI 0.50–0.85, P<.001
PFS (PIK3CA-wildtype, n=231): 7.4 vs 5.6mo, HR 0.85 — not significant
ORR (PIK3CA-mut): 26.6% vs 12.8%

Adverse events

Metabolic: Grade ≥3 hyperglycemia 36.6% vs 0.7% (requires metformin prophylaxis)
Dermatologic: Grade ≥3 rash 9.9%
GI: Grade ≥3 diarrhea 6.7%
Tolerability: Dose reduction 56.7%; discontinuation 25.0%; serious AEs significantly more frequent in alpelisib arm

Conclusions

Alpelisib + fulvestrant significantly improved PFS in PIK3CA-mutated HR+ HER2- advanced BC after prior ET. Validated PI3Kα inhibition as a biomarker-driven strategy. No OS benefit demonstrated.

Key Limitations

No OS benefit; modest 11-month PFS in heavily pretreated population. High grade ≥3 hyperglycemia (36.6%) requires proactive diabetes management and glucose monitoring each cycle — significant burden, contraindicated in uncontrolled diabetes. Rash (rarely Stevens-Johnson) is class-specific. No benefit in PIK3CA-wildtype — biomarker-restricted. Newer AKT inhibitors (capivasertib) and inavolisib may offer better profiles.

Clinical Context

Alpelisib (Piqray) + fulvestrant: FDA approved 2019 for PIK3CA-mutated HR+ HER2- advanced BC after prior endocrine therapy. PIK3CA testing (ctDNA or tissue) required. ESMO-MCBS 3. Capivasertib, inavolisib, and oral SERDs have since entered the space and may supplant alpelisib given improved tolerability.

References